GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

Progress in targeted signaling inhibition and immunotherapy has spurred a race to transform treatment across virtually all cancer disease sites. There is ample preclinical data pointing toward the ...

Researchers at Intermountain Health have been awarded a $356,000 grant from Merck, a global science and technology company ...

Carom seeds (ajwain) are called seeds, but they're fruit from the ajwain herb. You can eat the seeds or use them as a spice.

Saunas can help boost your immune system, lower blood pressure, improve your mood, and relieve pain. Here's how to reap the ...

Blocking acetylcholine prevents involuntary muscle movements in the lungs, gastrointestinal tract, urinary tract ... who were taking at least one anticholinergic drug showed lower scores on memory and ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...